Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Historical Acquisition Tree
Key: Sygnis Bioscience GmbH & Co KG (1) Acquired (1)
sargramostim (leukine) (2 trials)
sodium chloride (1 trial)
Cerebral Infarction (Phase 2)
Ischemia (Phase 2)
Stroke (Phase 2)
Trials (2 total)
Trial APIs (2 total)